Carla Casulo, MD, of the James P. Wilmot Cancer Center, discusses findings on POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma, using data from more than 5,000 patients in 13 clinical trials (Abstract 412).
Jia Ruan, MD, of NewYork-Presbyterian/Weill Cornell Medical Center, discusses a 5-year follow-up analysis that showed lenalidomide and rituximab as initial treatment achieved a high rate of complete responses and MRD negativity with durable remissions beyond 4 years (Abstract 154).
Joseph M. Connors, MD, of the British Columbia Cancer Agency, discusses study findings on a new front-line option: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with previously untreated stage III or IV Hodgkin lymphoma (Abstract 6).
Andrew M. Evens, DO, of Tufts University, discusses findings on the effectiveness of DLBCL-based therapy for patients whose disease fell between diffuse large B-cell and classical Hodgkin lymphoma (Abstract 375).
Brian T. Hill, MD, PhD, of the Cleveland Clinic, discusses study findings that showed consolidation with autologous hematopoietic cell transplant in the first remission improves overall survival in patients younger than age 65 (Abstract 341).
John F. Seymour, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses an interim analysis of venetoclax plus rituximab vs bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA-2).
